Fate Therapeutics (FATE) Misses Q1 EPS by 4c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Samsung 2q Oper Profit 89.40t Won, Est. 84.2t Won
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance